ELCC 2019 - Strong intracranial efficacy emerges from combined data of entrectinib in ROS1 fusion-positive NSCLC


  • Michael Simm
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

The combined analysis of 134 patients with ROS1 fusion-positive NSCLC who participated in phase 1/2 trials showed entrectinib to have strong intracranial efficacy be well-tolerated with a manageable safety profile.

Why this matters

Brain metastases are frequent in patients with ROS1 fusion-positive NSCLC. Entrectenib is a potent inhibitor of ROS1 and was designed to penetrate the brain. It achieved therapeutic levels in multiple intracranial tumor models.

Study design

Updated and integrated safety and efficacy data from 3 phase 1/2 studies with entrectinib in 134 patients with locally advanced/metastatic ROS1 fusion-positive NSCLC (ALKA-372-001, STARTRK-1, and STARTRK-2).

Key results

  • Treatment-related adverse events (AE) were seen in 93% of patients. Of these AE, 4% were grade 4, 31% were grade 3, and 59% were grade 1 or 2.
  • Dose reductions were necessary in 34% of patients, discontinuation in 5%.
  • Efficacy data are from 53 patients, of whom 23 had CNS metastases.
  • ORR: 77.4%; median duration of response 24.6 months, median PFS 19 months, (median OS has not been reached).
  • Duration of response and PFS were roughly twice as long for patients without CNS disease at baseline, but intracranial ORR was 55% with 20% CR.

Funding

Ignyta, Inc., a wholly owned subsidiary of F. Hoffmann-La Roche Ltd.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit